DENVER, Nov. 15, 2017 (GLOBE NEWSWIRE) — According to Grand View Research the US CBD market will be a $2.1 billion industry by 2020. With this consumer demand showing no signs of stopping why are medical professionals so reluctant to embrace cannabidiol (CBD)?
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/248cb252-27a8-49a7-925d-2c95e469ad62
Blair, a West Point graduate, retired US Army Colonel and Medical Doctor understands the reluctance.
“I’ve never taken THC or marijuana,” says Blair referencing his many years of being drug tested as a medical doctor in the military.
After his retirement from the US Army, Dr. Blair found traditional medicines were exacerbating his patients’ problems rather than fixing them. For himself, his family and his patients, Dr. Blair began utilizing CBD.
“One of the main problems is that our medical profession lacks any significant understanding of the endocannabinoid system… there is a general ignorance about it,” said Colonel Philip Blair MD in Newsweek’s special edition titled “Weed.”
Dr. Blair is ahead of the curve for educating medical professionals. So far in 2017, Blair has reached over 10,000 medical professionals at conferences and seminars ranging from gut health to mental health to skin care. Every conference starts with the same theme: a balanced endocannabinoid system is a balanced body.
But it isn’t just the science slowing down medical professionals, culture is at fault as well.
“They’ve [medical professionals] been caught up in the negative propaganda,” he continued.
Despite these challenges, Dr. Blair remains hopeful that science will prevail over prejudice.
“There is quite a bit of research that has been done on cannabidiol,” says Dr. Blair.
For Dr. Blair, the research and his patients’ experiences all add up to one thing: there are many uses for CBD.
“There’s no need for weed,” he states, referencing CBD’s “healthy not high” reputation among athletes and wellness enthusiasts.
The entire article is available in the Newsweek Special Edition titled Weed available online and at newsstands.
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products in 27 countries including United States, Japan, Puerto Rico, Brazil and throughout Europe. More information available at Elixinol.com.
+1 844-804-3504 ext 420